A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05487235 |
|
Recruitment Status :
Recruiting
First Posted : August 4, 2022
Last Update Posted : April 12, 2024
|
Sponsor:
Genentech, Inc.
Information provided by (Responsible Party):
Genentech, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of GDC-1971 when administered in combination with atezolizumab in participants with locally advanced or metastatic solid tumors.
The study will have 2 stages- dose finding stage and expansion stage. In expansion stage participants with non-small cell lung cancer programmed death ligand -1 high (NSCLC PD L-1 high), NSCLC PD L-1 low, head and neck squamous cell carcinoma (HNSCC) PD L-1 positive, BRAF wild type (BRAF WT) melanoma and any locally advanced or metastatic solid tumors will be enrolled.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Solid Tumors Metastatic Solid Tumors | Drug: GDC-1971 Drug: Atezolizumab Drug: Omeprazole | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 232 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors |
| Actual Study Start Date : | August 17, 2022 |
| Estimated Primary Completion Date : | May 31, 2025 |
| Estimated Study Completion Date : | May 31, 2025 |
Resource links provided by the National Library of Medicine
Drug Information
available for:
Atezolizumab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Dose-finding Stage: GDC-1971
Participants will receive GDC-1971 tablet or capsule at assigned dose, orally once daily (QD) on Days 1-21 of each cycle, along with atezolizumab 1200 milligrams (mg) intravenous (IV) infusion once every 3 weeks (Q3W), until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet versus (vs) capsule formulations.
|
Drug: GDC-1971
Capsule or tablet administered orally.
Other Name: RO7517834, RLY-1971 Drug: Atezolizumab Administered as IV infusion.
Other Name: RO5541267 |
|
Experimental: Expansion Stage: GDC-1971
Participants will receive GDC-1971 orally at the assigned dose QD on Days 1-21 of each cycle and atezolizumab 1200 mg IV on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet vs capsule formulation, the effect of food and acid-reducing agents on GDC-1971.
|
Drug: GDC-1971
Capsule or tablet administered orally.
Other Name: RO7517834, RLY-1971 Drug: Atezolizumab Administered as IV infusion.
Other Name: RO5541267 Drug: Omeprazole Administered orally as tablet or capsule in the acid-reducing agent assessment. |
Primary Outcome Measures :
- Percentage of Participants With Adverse Events (AEs) [ Time Frame: Up to approximately 2.5 years ]
- Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs [ Time Frame: Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years) ]
- Percentage of Participants With Clinically Significant Change from Baseline in Clinical Laboratory Test Results [ Time Frame: Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years) ]
- Percentage of Participants With Clinically Significant Change From Baseline in RR and QT Intervals as Measured by Electrocardiogram (ECG) [ Time Frame: Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years) ]
- Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) [ Time Frame: From Day 1 to Day 21 of Cycle 1 of the dose finding stage ]
- Plasma Concentration of GDC-1971 [ Time Frame: Up to approximately 2.5 years ]
Secondary Outcome Measures :
- Area Under the Concentration-Time Curve From Time 0 to 96 hours (AUC0-96 hr) Following GDC-1971 Capsule or Tablet Administration [ Time Frame: Up to approximately 2.5 years ]
- AUC From Time 0 to Infinity (AUCinf) Following GDC-1971 Capsule or Tablet Administration [ Time Frame: Up to approximately 2.5 years ]
- Cmax of GDC-1971 Following Capsule or Tablet Administration [ Time Frame: Up to approximately 2.5 years ]
- AUC 0-96 hr Following GDC-1971 Tablet Administration Under Fasted and Fed Conditions [ Time Frame: Up to approximately 2.5 years ]
- AUC inf Following GDC-1971 Tablet Administration Under Fasted and Fed Conditions [ Time Frame: Up to approximately 2.5 years ]
- Cmax of GDC-1971 Following Tablet Administration Under Fasted and Fed Conditions [ Time Frame: Up to approximately 2.5 years ]
- AUC 0-24 hr at Steady State Following GDC-1971 Tablet Administration and in Combination With Omeprazole [ Time Frame: Up to approximately 2.5 years ]
- Cmax at Steady State Following GDC-1971 Tablet Administration and in Combination With Omeprazole [ Time Frame: Up to approximately 2.5 years ]
- Objective Response Rate (ORR) [ Time Frame: Up to approximately 2.5 years ]
- Duration of Response (DOR) [ Time Frame: Up to approximately 2.5 years ]
- Progression Free Survival (PFS) [ Time Frame: Up to approximately 2.5 years ]
- PFS Rate [ Time Frame: Month 6 ]
- Overall Survival (OS) Rate [ Time Frame: Months 6 and 12 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Has Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1
- Has Life expectancy >= 12 weeks
- Adequate organ function
- Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
Inclusion Criteria for Dose-Finding Stage:
- Histologically confirmed locally advanced or metastatic solid tumor that has progressed after at least one available standard therapy or for which approved standard therapy has proven to be ineffective or intolerable
Inclusion Criteria for Expansion Stage: NSCLC Cohort
- Histologically confirmed locally advanced or metastatic NSCLC
- Absence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)
- PD- L1 positive
- No prior systemic therapy for locally advanced or metastatic NSCLC
Inclusion Criteria for Expansion Stage: HNSCC Cohort
- Histologically confirmed recurrent, or metastatic HNSCC
- PD-L1 positive
- No prior systemic therapy for recurrent or metastatic HNSCC
Inclusion Criteria for Expansion Stage: BRAF WT melanoma Cohort
- Histologically confirmed locally advanced or metastatic or unresectable locally advanced cutaneous BRAF WT melanoma or melanomas of unknown primary that are non-mucosal and non -uveal that has progressed on or after treatment that included anti PD1 or anti PD-L1 therapy
Inclusion Criteria for Expansion Stage: Other Advanced or Metastatic Solid Tumors Cohort
- Histologically confirmed locally advanced or metastatic solid tumor that has progressed after at least one available standard therapy or for which approved standard therapy has proven to be ineffective or intolerable, standard therapy is considered inappropriate, or an investigational agent is a recognized standard of care
Exclusion Criteria:
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
- Has leptomeningeal disease or carcinomatous meningitis
- Has uncontrolled hypertension
- Has left ventricular ejection fraction < institutional lower limit of normal or < 50%
- Has clinically significant history of liver disease including viral or other hepatitis, current alcohol abuse, or cirrhosis
- Has an active or history of autoimmune disease or immune deficiency including myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or multiple sclerosis. Participants with a history of autoimmune- related hypothyroidism on thyroid replacement hormone or with controlled Type I diabetes mellitus on a stable dose of an insulin regimen are eligible for this study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05487235
Contacts
| Contact: GO43712 https://forpatients.roche.com/ | 888-662-6728 (U.S. Only) | global-roche-genentech-trials@gene.com |
Locations
Show 38 study locations
Sponsors and Collaborators
Genentech, Inc.
Investigators
| Study Director: | Clinical Trials | Hoffmann-La Roche |
| Responsible Party: | Genentech, Inc. |
| ClinicalTrials.gov Identifier: | NCT05487235 |
| Other Study ID Numbers: |
GO43712 2021-006479-40 ( EudraCT Number ) |
| First Posted: | August 4, 2022 Key Record Dates |
| Last Update Posted: | April 12, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Neoplasms Atezolizumab Omeprazole Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological |
Antineoplastic Agents Anti-Ulcer Agents Gastrointestinal Agents Proton Pump Inhibitors Enzyme Inhibitors |